Wissen - Life Sciences News - Topics - Downloads - Newsletter
Contact
Rob Stijlen
Rob Stijlen
Home | Financial year 2018 – ARCONDIS Group doubles its revenue in Germany
March 9, 2019

Financial year 2018 – ARCONDIS Group doubles its revenue in Germany

Basel/Frankfurt/Munich, March, 2019

The consulting firm ARCONDIS, which specializes in the life sciences industry, has wrapped up its 17th fiscal year with a group revenue of 24 million Swiss francs. This corresponds to an increase of 9% on the previous year.

The German ARCONDIS GmbH, which has subsidiaries in Frankfurt and Munich, had a hugely successful 2018. It generated a revenue of 5.2 million Euros and recorded +42% growth. This excellent result is primarily due to the company’s customer portfolio: as in the previous year, ARCONDIS Germany strengthened its business with its major customers, which include five of the biggest players in the pharmaceutical industry.

The consultancy firm continued to support global IT and compliance projects for one of the world’s largest manufacturers of medical devices and chemicals.

Peter Bunse, Managing Director of ARCONDIS GmbH, plans to hire new employees in 2019 to keep abreast of the stable, high demand for services specific to the life sciences.

ARCONDIS AG, too, successfully achieved solid growth from an already high level. With more than a hundred employees, the Swiss parent company generated a revenue of 19.5 million Swiss Francs in 2018, which corresponds to a growth rate of 4%. Strategic consulting assignments regarding the digital transformation and regulatory requirements, topics that have played an established role with major life sciences companies for many years, are becoming increasingly important. Besides the medical device regulation (MDR) and the serialization requirements laid out in the falsified medicines directive (FMD), the data protection requirements of the EU GDPR were particularly relevant to the life sciences industry last year.

“In 2019, we will focus on ensuring that our customers benefit from the advantages offered by digitalization. We use the umbrella term Life Sciences 4.1 to describe the corresponding technologies and measures in a highly customer-specific way that take compliance aspects into account,” Christian Baumgartner, Founder and President of the Supervisory Board of the ARCONDIS Group, commented.

Financial Year 2018 - Christian Baumgartner